CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients
- PMID: 24129368
- DOI: 10.1097/QAI.0000000000000001
CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients
Abstract
Objective: HIV-infected patients receiving antiretroviral treatment frequently accumulate fat at the abdominal level. It is unknown whether T-cell activation and immune phenotypes are associated with fat accumulation. Thus, the aim of the study was to search for an association between the presence of clinical lipodystrophy (LD), visceral and subcutaneous abdominal adipose tissue amount (VAT and SAT), and peripheral T-cell immune phenotypes.
Design: Cross-sectional study including 87 HIV-infected antiretroviral therapy-treated virologically suppressed and immune-reconstituted patients.
Methods: The patients were evaluated for clinical LD, VAT, SAT, homeostasis model of insulin resistance, and coronary artery calcium score (>10). T-cell activation (CD8/CD38), differentiation (CD4/CD8/CCR7/CD45RA), and expression/activation of the interleukin-7 (IL-7)/IL-7R system (CD4/CD8/CD127, IL-7, and CD4/CD8/pStat-5) were assessed by cytometry.
Results: In multivariable analyses, CD8 T-cell activation (CD38) was associated with lipoatrophy and central fat accumulation (respectively, β = 5.63, P = 0.005, and β = 4.19, P = 0.020). This was also the case for IL-7R expressing CD8⁺ T cells (CD127⁺) for lipoatrophy β = 12.8, P = 0.003, and for central fat accumulation β = 9.45, P = 0.016. CD8⁺ T-cell activation was also associated with VAT/total adipose tissue (β = 0.01, P = 0.002) and SAT/VAT ratios (β = -0.014, P = 0.015). As expected, VAT/total adipose tissue was an independent risk factor for homeostasis model of insulin resistance (r = 0.364, P = 0.028) and cardiovascular risk (coronary artery calcium, r = 0.406, P = 0.002).
Conclusions: CD8⁺ T-cell activation was associated with LD and the relative amount of VAT in antiretroviral therapy-controlled, virologically suppressed, HIV-infected patients. We propose that CD8 activation may be involved in the accumulation of central fat frequently observed in these patients, with resulting increased cardiometabolic risk.
Similar articles
-
Magnetic resonance imaging evaluation of lipodystrophy in HIV-positive patients receiving highly active antiretroviral therapy.Int J STD AIDS. 2015 Jul;26(8):582-9. doi: 10.1177/0956462414546916. Epub 2014 Aug 18. Int J STD AIDS. 2015. PMID: 25139003
-
Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy.J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):142-8. doi: 10.1097/QAI.0b013e31829bdb67. J Acquir Immune Defic Syndr. 2013. PMID: 23714743
-
Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.Clin Drug Investig. 2019 Dec;39(12):1239-1249. doi: 10.1007/s40261-019-00840-2. Clin Drug Investig. 2019. PMID: 31531832 Free PMC article.
-
Treatment options for HIV-associated central fat accumulation.AIDS Patient Care STDS. 2009 Jan;23(1):5-18. doi: 10.1089/apc.2008.0067. AIDS Patient Care STDS. 2009. PMID: 19055407 Free PMC article. Review.
-
Adipose Tissue in HIV Infection.Compr Physiol. 2017 Sep 12;7(4):1339-1357. doi: 10.1002/cphy.c160028. Compr Physiol. 2017. PMID: 28915327 Free PMC article. Review.
Cited by
-
HIV-associated lipodystrophy: a review from a Brazilian perspective.Ther Clin Risk Manag. 2014 Jul 17;10:559-66. doi: 10.2147/TCRM.S35075. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 25083134 Free PMC article. Review.
-
Endocrinological aspects of HIV infection.J Endocrinol Invest. 2018 Aug;41(8):881-899. doi: 10.1007/s40618-017-0812-x. Epub 2018 Jan 8. J Endocrinol Invest. 2018. PMID: 29313284 Review.
-
Self-reported body fat change in HIV-infected men is a marker of decline in physical health-related quality of life with aging, independent of co-morbidity.PLoS One. 2014 Dec 1;9(12):e114166. doi: 10.1371/journal.pone.0114166. eCollection 2014. PLoS One. 2014. PMID: 25436612 Free PMC article.
-
HIV and antiretroviral therapy-related fat alterations.Nat Rev Dis Primers. 2020 Jun 18;6(1):48. doi: 10.1038/s41572-020-0181-1. Nat Rev Dis Primers. 2020. PMID: 32555389 Review.
-
Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.Clin Infect Dis. 2019 Apr 8;68(8):1394-1401. doi: 10.1093/cid/ciy716. Clin Infect Dis. 2019. PMID: 30137242 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials